Loading viewer...
conference
Format: PDF conference
Telix Pharmaceuticals presented at the J.P. Morgan Healthcare Conference in January 2023, showcasing its commercial-stage radiopharmaceutical portfolio including the FDA-approved Illuccix for prostate cancer imaging. The company highlighted its industry-leading theranostic pipeline with over 20 active clinical studies, US$100.4M in U.S. sales since April 2022 launch, and plans for expanded manufacturing capacity.
annual_report
14 Pages
conference
22 Pages
SenesTech
Helix Energy Solutions 2017 Raymond James Conference
conferenceconference
28 Pages
Helix Energy Solutions
Keppel Infrastructure Trust 2024 HSBC MENAT Forum
conferenceconference
47 Pages
Keppel Infrastructure Trust